{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:52:45Z","timestamp":1772034765599,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urol Nephrol"],"DOI":"10.1007\/s11255-025-04767-w","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T17:49:50Z","timestamp":1756403390000},"page":"895-903","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Two different protocols in single, immediate, postoperative intravesical chemotherapy after transurethral resection in suspected, low-risk, non-muscle-invasive bladder cancer"],"prefix":"10.1007","volume":"58","author":[{"given":"Ali Kaan","family":"Yildiz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arif","family":"Bayraktar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Turgay","family":"Kacan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Demirhan Orsan","family":"Demir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Gokkurt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer Furkan","family":"Erbay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bugra Bilge","family":"Keseroglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berat Cem","family":"Ozgur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer Gokhan","family":"Doluoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tolga","family":"Karakan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"issue":"9","key":"4767_CR1","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1002\/cncr.22224","volume":"107","author":"EM Messing","year":"2006","unstructured":"Messing EM, Madeb R, Young T, Gilchrist KW, Bram L, Greenberg EB et al (2006) Long-term outcome of hematuria home screening for bladder cancer in men. Cancer 107(9):2173\u20132179. https:\/\/doi.org\/10.1002\/cncr.22224","journal-title":"Cancer"},{"issue":"1","key":"4767_CR2","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Dominguez Escrig JL et al (2022) European association of urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ). Eur Urol 81(1):75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"issue":"4","key":"4767_CR3","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1097\/ju.0000000000003846","volume":"211","author":"JM Holzbeierlein","year":"2024","unstructured":"Holzbeierlein JM, Bixler BR, Buckley DI, Chang SS, Holmes R, James AC et al (2024) Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment. J Urol 211(4):533\u2013538. https:\/\/doi.org\/10.1097\/ju.0000000000003846","journal-title":"J Urol"},{"issue":"3","key":"4767_CR4","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1097\/01.ju.0000168657.51551.49","volume":"174","author":"CP Brocks","year":"2005","unstructured":"Brocks CP, B\u00fcttner H, B\u00f6hle A (2005) Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol 174(3):1115\u20131118. https:\/\/doi.org\/10.1097\/01.ju.0000168657.51551.49","journal-title":"J Urol"},{"issue":"5","key":"4767_CR5","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.juro.2011.12.056","volume":"187","author":"MS Cookson","year":"2012","unstructured":"Cookson MS, Chang SS, Oefelein MG, Gallagher JR, Schwartz B, Heap K (2012) National practice patterns for immediate postoperative instillation of chemotherapy in nonmuscle invasive bladder cancer. J Urol 187(5):1571\u20131576. https:\/\/doi.org\/10.1016\/j.juro.2011.12.056","journal-title":"J Urol"},{"issue":"6","key":"4767_CR6","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1016\/j.juro.2012.08.044","volume":"188","author":"FN Burks","year":"2012","unstructured":"Burks FN, Liu AB, Suh RS, Schuster TG, Bradford T, Moylan DA et al (2012) Understanding the use of immediate intravesical chemotherapy for patients with bladder cancer. J Urol 188(6):2108\u20132113. https:\/\/doi.org\/10.1016\/j.juro.2012.08.044","journal-title":"J Urol"},{"issue":"23","key":"4767_CR7","doi-asserted-by":"publisher","first-page":"5392","DOI":"10.1002\/cncr.26198","volume":"117","author":"K Chamie","year":"2011","unstructured":"Chamie K, Saigal CS, Lai J, Hanley JM, Setodji CM, Konety BR et al (2011) Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117(23):5392\u20135401. https:\/\/doi.org\/10.1002\/cncr.26198","journal-title":"Cancer"},{"issue":"5","key":"4767_CR8","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.eururo.2019.08.016","volume":"76","author":"M Babjuk","year":"2019","unstructured":"Babjuk M, Burger M, Comp\u00e9rat EM, Gontero P, Mostafid AH, Palou J et al (2019) European association of urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ) - 2019 update. Eur Urol 76(5):639\u2013657. https:\/\/doi.org\/10.1016\/j.eururo.2019.08.016","journal-title":"Eur Urol"},{"issue":"4","key":"4767_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00002512-199915040-00006","volume":"15","author":"SV Onrust","year":"1999","unstructured":"Onrust SV, Wiseman LR, Goa KL (1999) Epirubicin: a review of its intravesical use in superficial bladder cancer. Drugs Aging 15(4):307\u2013333. https:\/\/doi.org\/10.2165\/00002512-199915040-00006","journal-title":"Drugs Aging"},{"issue":"4","key":"4767_CR10","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/S0022-5347(17)36198-0","volume":"149","author":"W Oosterlinck","year":"1993","unstructured":"Oosterlinck W, Kurth KH, Schr\u00f6der F, Bultinck J, Hammond B, Sylvester R (1993) A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149(4):749\u2013752. https:\/\/doi.org\/10.1016\/S0022-5347(17)36198-0","journal-title":"J Urol"},{"issue":"3","key":"4767_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0022-5347(05)64556-9","volume":"168","author":"P Rajala","year":"2002","unstructured":"Rajala P, Kaasinen E, Raitanen M, Liukkonen T, Rintala E (2002) Perioperative single dose instillation of epirubicin or interferon-\u03b1 after transurethral resection for the prophylaxis of primary superficial bladder cancer recurrence: a prospective randomized multicenter study\u2014finnbladder III long-term results. J Urol 168(3):981\u2013985. https:\/\/doi.org\/10.1016\/S0022-5347(05)64556-9","journal-title":"J Urol"},{"issue":"18","key":"4767_CR12","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/bf03262330","volume":"21","author":"MF Botteman","year":"2003","unstructured":"Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003) The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 21(18):1315\u20131330. https:\/\/doi.org\/10.1007\/bf03262330","journal-title":"Pharmacoeconomics"},{"key":"4767_CR13","first-page":"9","volume":"3","author":"JS Jones","year":"2007","unstructured":"Jones JS, Campbell S (2007) Non-muscle-invasive bladder cancer (Ta, T1, and CIS). Campbell-Walsh Urology 3:9","journal-title":"Campbell-Walsh Urology"},{"issue":"1","key":"4767_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.juro.2012.03.007","volume":"188","author":"HB Grossman","year":"2012","unstructured":"Grossman HB, Stenzl A, Fradet Y, Mynderse LA, Kriegmair M, Witjes JA et al (2012) Long-term decrease in bladder cancer recurrence with hexaminolevulinate enabled fluorescence cystoscopy. J Urol 188(1):58\u201362. https:\/\/doi.org\/10.1016\/j.juro.2012.03.007","journal-title":"J Urol"},{"issue":"4","key":"4767_CR15","doi-asserted-by":"publisher","first-page":"477","DOI":"10.6004\/jnccn.2013.0060","volume":"11","author":"MR Abern","year":"2013","unstructured":"Abern MR, Owusu RA, Anderson MR, Rampersaud EN, Inman BA (2013) Perioperative intravesical chemotherapy in non-muscle-invasive bladder cancer: a systematic review and meta-analysis. J Natl Compr Canc Netw 11(4):477\u2013484. https:\/\/doi.org\/10.6004\/jnccn.2013.0060","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4767_CR16","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.eururo.2013.06.009","volume":"64","author":"N Perlis","year":"2013","unstructured":"Perlis N, Zlotta AR, Beyene J, Finelli A, Fleshner NE, Kulkarni GS (2013) Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review. Eur Urol 64(3):421\u2013430. https:\/\/doi.org\/10.1016\/j.eururo.2013.06.009","journal-title":"Eur Urol"},{"issue":"1","key":"4767_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.juro.2007.08.166","volume":"179","author":"I Berrum-Svennung","year":"2008","unstructured":"Berrum-Svennung I, Granfors T, Jahnson S, Boman H, Holm\u00e4ng S (2008) A single instillation of epirubicin after transurethral resection of bladder tumors prevents only small recurrences. J Urol 179(1):101\u2013105. https:\/\/doi.org\/10.1016\/j.juro.2007.08.166","journal-title":"J Urol"},{"issue":"5","key":"4767_CR18","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1046\/j.1464-410X.1997.00142.x","volume":"79","author":"B Ali-el-Dein","year":"1997","unstructured":"Ali-el-Dein B, Nabeeh A, El-Baz M, Shamaa S, Ashamallah A (1997) Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa and pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol 79(5):731\u2013735. https:\/\/doi.org\/10.1046\/j.1464-410X.1997.00142.x","journal-title":"Br J Urol"},{"issue":"4","key":"4767_CR19","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.eururo.2009.01.006","volume":"55","author":"S Gudj\u00f3nsson","year":"2009","unstructured":"Gudj\u00f3nsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T et al (2009) Should all patients with non\u2013muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol 55(4):773\u2013780","journal-title":"Eur Urol"},{"issue":"2","key":"4767_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.eururo.2015.05.050","volume":"69","author":"RJ Sylvester","year":"2016","unstructured":"Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S et al (2016) Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol 69(2):231\u2013244. https:\/\/doi.org\/10.1016\/j.eururo.2015.05.050","journal-title":"Eur Urol"},{"key":"4767_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13133789","author":"S Chiujdea","year":"2024","unstructured":"Chiujdea S, Ferro M, Vartolomei MD, Lucarelli G, Bekku K, Matsukawa A et al (2024) Epirubicin and non-muscle invasive bladder cancer treatment: a systematic review. J Clin Med. https:\/\/doi.org\/10.3390\/jcm13133789","journal-title":"J Clin Med"},{"issue":"3","key":"4767_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/j.1464-410X.2004.04884.x","volume":"94","author":"K Mitsumori","year":"2004","unstructured":"Mitsumori K, Tsuchiya N, Habuchi T, Li Z, Akao T, Ohyama C et al (2004) Early and large-dose intravesical instillation of epirubicin to prevent superficial bladder carcinoma recurrence after transurethral resection. BJU Int 94(3):317\u2013321. https:\/\/doi.org\/10.1111\/j.1464-410X.2004.04884.x","journal-title":"BJU Int"},{"issue":"3","key":"4767_CR23","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1159\/000019581","volume":"33","author":"K Okamura","year":"1998","unstructured":"Okamura K, Kinukawa T, Tsumura Y, Otani T, Itoh H, Kobayashi H et al (1998) A randomized study of short-versus long-term intravesical epirubicin instillation for superficial bladder cancer. Nagoya University Urological Oncology Group. Eur Urol 33(3):285\u2013288. https:\/\/doi.org\/10.1159\/000019581","journal-title":"Eur Urol"},{"issue":"1","key":"4767_CR24","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/bf00686922","volume":"35","author":"O Ryoji","year":"1994","unstructured":"Ryoji O, Toma H, Nakazawa H, Goya N, Okumura T, Sonoda T et al (1994) A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer, Tokyo Women\u2019s Medical College bladder cancer collaborating group. Cancer Chemotherap Pharmacol 35(1):60\u201364. https:\/\/doi.org\/10.1007\/bf00686922","journal-title":"Cancer Chemotherap Pharmacol"},{"issue":"1","key":"4767_CR25","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/bf00686919","volume":"35","author":"H Eto","year":"1994","unstructured":"Eto H, Oka Y, Ueno K, Nakamura I, Yoshimura K, Arakawa S et al (1994) Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group. Cancer Chemother Pharmacol 35(1):46\u201351. https:\/\/doi.org\/10.1007\/bf00686919","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"4767_CR26","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/s0022-5347(17)37240-3","volume":"147","author":"MD Melekos","year":"1992","unstructured":"Melekos MD, Dauaher H, Fokaefs E, Barbalias G (1992) Intravesical instillations of 4-epi-doxorubicin (epirubicin) in the prophylactic treatment of superficial bladder cancer: results of a controlled prospective study. J Urol 147(2):371\u2013375. https:\/\/doi.org\/10.1016\/s0022-5347(17)37240-3","journal-title":"J Urol"},{"issue":"Suppl 2","key":"4767_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5301\/uro.5000193","volume":"83","author":"M Ragonese","year":"2016","unstructured":"Ragonese M, Racioppi M, Bassi PF, Di Gianfrancesco L, Lenci N, Filianoti A et al (2016) Mitomycin C: new strategies to improve efficacy of a well-known therapy. Urologia 83(Suppl 2):24\u201328. https:\/\/doi.org\/10.5301\/uro.5000193","journal-title":"Urologia"},{"issue":"8","key":"4767_CR28","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1093\/jnci\/93.8.597","volume":"93","author":"JL Au","year":"2001","unstructured":"Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL et al (2001) Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 93(8):597\u2013604. https:\/\/doi.org\/10.1093\/jnci\/93.8.597","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4767_CR29","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/00365599109024524","volume":"25","author":"O Lukkarinen","year":"1991","unstructured":"Lukkarinen O, Paul C, Hellstr\u00f6m P, Kontturi M, Nurmi M, Puntala P et al (1991) Intravesical epirubicin with and without verapamil for the prophylaxis of superficial bladder tumours. Scand J Urol Nephrol 25(1):25\u201328. https:\/\/doi.org\/10.3109\/00365599109024524","journal-title":"Scand J Urol Nephrol"},{"issue":"2","key":"4767_CR30","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1159\/000474054","volume":"9","author":"H Huland","year":"1983","unstructured":"Huland H, Otto U (1983) Mitomycin instillation to prevent recurrence of superficial bladder carcinoma. Results of a controlled, prospective study in 58 patients. European Urol 9(2):84\u201386. https:\/\/doi.org\/10.1159\/000474054","journal-title":"European Urol"}],"container-title":["International Urology and Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04767-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11255-025-04767-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11255-025-04767-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T14:30:49Z","timestamp":1772029849000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11255-025-04767-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":30,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["4767"],"URL":"https:\/\/doi.org\/10.1007\/s11255-025-04767-w","relation":{},"ISSN":["1573-2584"],"issn-type":[{"value":"1573-2584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"7 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}